Rheumatoid Arthritis Treatment Market Outlook:
Rheumatoid Arthritis Treatment Market size was over USD 36 billion in 2024 and is estimated to reach USD 78 billion by the end of 2037, expanding at a CAGR of 6.9% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of rheumatoid arthritis treatment is estimated at USD 38 billion.
In 2024, the global RA patient population was over 16 million. The supply chain of RA therapies is extremely internationalized. Manufacturers tend to hold approximately 17-25 months of safety stock for APIs. In 2023, the Producer Price Index (PPI) for pharmaceutical preparations, which include RA drugs, was 2% higher. During this time, the Consumer Price Index (CPI) for prescription medicines was 3.2% higher. Product price levels were maintained, and government auditors reported drug class price inflation was 1.3% higher than overall medicine price inflation.
R&D expenditure for RA treatments currently exceeds USD 1 billion per year globally. The FDA further reports over 1,100 Drug Master Files (DMFs) for RA APIs submitted in the last 24 months. This reflects a diverse range of regulatory variety and activity. Trade in APIs (Raw Medicines) for RA drugs provides us with significant import-export volumes. Finished dosage forms were mostly exported from the EU. In the U.S. to the developing markets, raw materials generally make their way through multi-modal supply chains.
